Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL511591 | 0.95 | POLB (0.83) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL8150863 | 0.93 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL510431 | 0.93 | POLB (0.80) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL293402 | 0.89 | POLB (0.72) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7006523 | 0.89 | POLB (1.00) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7854448 | 0.89 | POLB (0.92) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL28706592 | 0.87 | POLB (0.70) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7856311 | 0.87 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7854826 | 0.87 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 | |
| SCHEMBL7856315 | 0.87 | POLB (0.96) | POLBNPC1RAB9ADDAH1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425741-A | Jatrorrhizine derivative with antibacterial activity, synthesis method and application | 西南大学 | 2023-07-14 | — | — | CN | claimed |
| CN-116425741-A | Jatrorrhizine derivative with antibacterial activity, synthesis method and application | 西南大学 | 2023-07-14 | — | — | CN | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| CN-101384532-B | method for producing optically active alcohol | KOTOBUKI PHARMACEUTICAL CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102702182-A | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102558140-A | Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1988071-A1 | METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL | Kotobuki Pharmaceutical Co., Ltd. (JP) | 2008-11-05 | — | — | EP | disclosed |
| CN-101258147-A | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| CN-1284075-A | Novel compounds having CGMP-PDE inhibitory effect | MOCHIDA PHARM CO LTD (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| CN-1136556-A | Aromatic group substituted W-amino alkyl amide and alkyl amide | CIBA GEIGY CO LTD (CH) | 1996-11-27 | — | — | CN | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062527-A1 | Process for Preparing Optically Active Alcohols | ADH1C, ADH1A, ADH5 | POLB 1478/4885NPC1 3609/4885RAB9A 452/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | POLB 3667/4885NPC1 436/4885RAB9A 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.